177 related articles for article (PubMed ID: 9785130)
21. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
22. [Morphologic endometrium changes with tamoxifen].
Dallenbach-Hellweg G; Hahn U; Schmidt D
Zentralbl Gynakol; 1996; 118(6):365-9. PubMed ID: 8768015
[TBL] [Abstract][Full Text] [Related]
23. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
24. Endometrial polyps during menopause: characterization and significance.
Orvieto R; Bar-Hava I; Dicker D; Bar J; Ben-Rafael Z; Neri A
Acta Obstet Gynecol Scand; 1999 Nov; 78(10):883-6. PubMed ID: 10577618
[TBL] [Abstract][Full Text] [Related]
25. MR appearance of endometrial carcinoma and mucinous cystadenoma in a postmenopausal patient treated with tamoxifen for breast cancer.
Joja I; Asakawa T; Ando Y; Shiraiwa M; Shibutani O; Akaki S; Kuroda M; Mizutani Y; Kudo T; Hiraki Y
Radiat Med; 1998; 16(4):315-9. PubMed ID: 9814431
[TBL] [Abstract][Full Text] [Related]
26. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA
Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927
[TBL] [Abstract][Full Text] [Related]
27. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
28. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
29. [Postmenopausal hemorrhage and endometrial cancer in tamoxifen therapy].
Krause A; Gerber B
Zentralbl Gynakol; 1994; 116(1):44-7. PubMed ID: 8147180
[TBL] [Abstract][Full Text] [Related]
30. Hormonal pathology of the endometrium.
Deligdisch L
Mod Pathol; 2000 Mar; 13(3):285-94. PubMed ID: 10757339
[TBL] [Abstract][Full Text] [Related]
31. [Endometrial cancers arising in polyps associated with tamoxifen use].
Mbatsogo BA; Le Bouëdec G; Michy T; Bourdel N; Fouilloux G; Dauplat J
Gynecol Obstet Fertil; 2005 Dec; 33(12):975-9. PubMed ID: 16321556
[TBL] [Abstract][Full Text] [Related]
32. Significance of "normal" endometrial cells in cervical cytology from asymptomatic postmenopausal women receiving hormone replacement therapy.
Montz FJ
Gynecol Oncol; 2001 Apr; 81(1):33-9. PubMed ID: 11277646
[TBL] [Abstract][Full Text] [Related]
33. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
Kesim MD; Aydin Y; Atis A; Mandiraci G
Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
[TBL] [Abstract][Full Text] [Related]
34. Endometrial pathologies associated with postmenopausal tamoxifen treatment.
Cohen I
Gynecol Oncol; 2004 Aug; 94(2):256-66. PubMed ID: 15297160
[TBL] [Abstract][Full Text] [Related]
35. [Primary multiple neoplasm of the endometrium and adjuvant hormone therapy in patients with breast cancer].
Bakhidze EV; Maksimov SIa; Barash NIu; Berstein LM; Semiglazov VF; Sheĭko EV; Novik VI
Vopr Onkol; 1998; 44(2):170-4. PubMed ID: 9615821
[TBL] [Abstract][Full Text] [Related]
36. Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.
Dal Cin P; Timmerman D; Van den Berghe I; Wanschura S; Kazmierczak B; Vergote I; Deprest J; Neven P; Moerman P; Bullerdiek J; Van den Berghe H
Cancer Res; 1998 Jun; 58(11):2278-81. PubMed ID: 9622058
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
Hachisuga T; Saito T; Kigawa J; Ohwada M; Yamazawa K; Yasue A; Iwasaka T; Sugiyama T; Kita T; Nagai N
Gynecol Oncol; 2004 Oct; 95(1):139-44. PubMed ID: 15385123
[TBL] [Abstract][Full Text] [Related]
38. [Hysteroscopic evaluation of the endometrium in 63 postmenopausal patients treated with tamoxifen for breast cancer].
Baldini B; Taddei GL; Tiso E; Visioli CB; Campos KJ; Napolitano AC; Tantini C
Minerva Ginecol; 1996 Jun; 48(6):259-62. PubMed ID: 8927287
[TBL] [Abstract][Full Text] [Related]
39. [Tamoxifen, endometrial cancer risk and liquid based cytology. A paradigmatic case].
Fambrini M; Buccoliero AM; Pieralli A; Andersson KL; Mattei A; Scarselli G; Taddei G; Marchionni M
Minerva Ginecol; 2011 Oct; 63(5):465-70. PubMed ID: 21926955
[TBL] [Abstract][Full Text] [Related]
40. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
